News

The European Lead Factory acknowledges the need for open exchange between researchers with different professional background and puts a focus on the career development of young scientists.

Just one month after publication, the Drug Discovery Today article by Karawajczyk et al describing the quality of the JECL public compounds has reached Top 5 of the most downloaded articles of this pr

Top Institute Pharma (TI Pharma), one of the partners in the EU Lead Factory, will be named Lygature as from January 1st 2016.

400,000 novel drug-like compounds are now compiled in the Joint European Compound Library (JECL); and 60 drug targets have been selected for screening.

The Honest Data Broker (HDB), a cloud-based informatics system, has been developed specifically to balance the intellectual property and scientific requirements of the consortium partners regarding the unique HTS screening and triage workflow within the EU Lead Factory.

They have been developed from a series of inhibitor compounds first identified by screening the JECL of the European Lead Factory against IOD1 and TDO, important targets in cancer immunotherapy.

Within 3 years after the launch of the European Lead Factory, the first patent protecting the outcomes of a drug target programme has been filed. The patent addresses multidrug resistance in bacterial infections. This important milestone reflects the EU Lead Factory’s ability to deliver on its promise, and highlights the potential of this shared-innovation approach to drug discovery.

Read the latest testimonial from a public drug target programme owner.

EU Lead Factory welcomes PostDocs and PhDs.

Independent reviewers acknowledged the achievements of EU Lead Factory as “highly significant” in the evaluation of the project’s midterm report.

Last week, Basel was the scientific hub for 3,000 scientists in the field of drug discovery. The Basel Life Science Week provided an opportunity not to be missed by the European Lead Factory. 

Partners of the European Lead Factory have published two articles highlighting the complexity of generating a competitive, diverse compound collection of high quality drug-like compounds.

Over 50 public target programmes have now been accepted for screening at the European Lead Factory. During the summer holidays, work at the European Lead Factory continued. 

The Chemical & Engineering News interviewed executives of the five chemistry CROs participating in the EU Lead Factory. 

A comprehensive overview on the EU Lead Factory as a successful experiment in collaborative drug discovery was recently published in the Journal of Medicines Development Sciences.